Literature DB >> 23474802

Acute gut GVHD in children: does skin involvement matter?

A Gassas1, L Sung, A Dupuis, T Schechter, M Egeler, M Ali.   

Abstract

Gut GVHD (G-GVHD) is frequently the most severe and difficult to treat compared with skin GVHD. It is unknown if skin involvement with G-GVHD has prognostic significance. To compare the prognosis of acute isolated G-GVHD vs acute gut and skin GVHD (GS-GVHD) in children following allo-SCT. Allo-SCT recipients from Jan 2000-Dec 2009 were included and patients who underwent endoscopy and gut biopsy for G-GVHD were identified. Four hundred and fifty children (0-18 years) underwent allo-SCT during the study period. Seventy-nine (17.5%) patients underwent endoscopy and biopsy. At least stage II was required for skin involvement. Forty nine patients had G-GVHD and 30 had combined, GS-GVHD. The majority of patients received CsA and MTX for GVHD prophylaxis. Sixty-seven percent of patients with GS-GVHD had grade III-IV while only 31% had grade III-IV in the G-GVHD group. Median follow-up was 6.3 years (range 3.6-11.9 years). Relapse rate was similar in both the groups. However, children with G-GVHD had a significantly higher risk of dying from GVHD related complications (37% vs 16%) resulting in superior survival for those with skin involvement (79% vs 49% P=0.02). Extension of G-GVHD to the skin may suggest a better outcome.

Entities:  

Mesh:

Year:  2013        PMID: 23474802     DOI: 10.1038/bmt.2013.15

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD.

Authors:  M Nadeau; S Perreault; S Seropian; F Foss; I Isufi; D L Cooper
Journal:  Bone Marrow Transplant       Date:  2015-10-19       Impact factor: 5.483

2.  Outcomes of high-grade gastrointestinal graft-versus-host disease posthematopoietic stem cell transplantation in children.

Authors:  Vedat Uygun; Dilara F K Uygun; Hayriye Daloğlu; Seda Irmak Öztürkmen; Gülsün Karasu; Volkan Hazar; Akif Yeşilipek
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.